Bayer To Highlight Oncology Franchise Research At ASCO 2017
WHIPPANY, N.J., May 17, 2017 /PRNewswire/ -- Bayer announced today that the latest research from across its growing oncology portfolio will be presented at the 53rdAnnual Meeting of the American Society of Clinical Oncology (ASCO), taking place June 2-6 in Chicago.
The data being presented at ASCO span prostate, colorectal, liver and thyroid cancers, as well as lymphomas, and includes a subgroup analysis from the Phase II CHRONOS-1 trial of copanlisib in patients with relapsed or refractory follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin's lymphoma (iNHL).1 Additional copanlisib data includes a Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive, fast-growing form of NHL. Earlier today, the U.S. Food and Drug Administration (FDA) granted Priority Review designation for Bayer's New Drug Application (NDA) for copanlisib for the treatment of relapsed or refractory FL patients who have received at least two prior therapies, based on the CHRONOS-1 data.
Other data of note includes interim results from the observational REASSURE trial examining real-world patient characteristics and treatment patterns with Xofigo®(radium Ra 223 dichloride) injection and a biomarker analysis from the Phase III RESORCE trial of Stivarga® (regorafenib) tablets. Stivarga recently received approval from the FDA for the treatment of HCC in patients previously treated with sorafenib, making it the first new treatment for HCC in a decade. Notable Bayer studies at ASCO 2017 include the following:
Radium-223 Dichloride (radium-223)
• Patient (pt) Characteristics and Treatment Patterns in the Radium (Ra)-223 REASSURE Observational Study
o Abstract #5042, Poster session: Genitourinary (Prostate) cancer (Hall A)
o Monday, June 5, 2017, 1:15 PM - 4:45 PM
Regorafenib
• Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study
o Abstract #3567, Poster session: Gastrointestinal (Colorectal) Cancer (Hall A)
o Saturday, June 3, 2017, 8:00 AM - 11:30 AM
• Hand–foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC)
o Abstract #3551, Poster session: Gastrointestinal (Colorectal) Cancer (Hall A)
o Saturday, June 3, 2017, 8:00 AM - 11:30 AM
• Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis
o Abstract #4078, Poster session: Gastrointestinal (nonCRC) (Hall A)
o Saturday, June 3, 2017, 8:00 AM - 11:30 AM
Sorafenib
• Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)
o Abstract #6084, Poster session: Head and Neck Cancer (Hall A)
o Monday, June 5, 2017 1:15 PM - 4:45 PM
Darolutamide
• ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)
o Abstract #TPS5092, Poster session: Genitourinary (Prostate) Cancer (Hall A)
o Monday, June 5, 2017 1:15 PM - 4:45 PM
Copanlisib
• Copanlisib in patients with relapsed or refractory follicular lymphoma
o Poster #7535, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia (Hall A) o Monday, June 5, 2017, 8:00 AM - 11:30 AM
• Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
o Poster #7536, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia (Hall A)
o Monday, June 5, 2017, 8:00 AM - 11:30 AM Other
• Treatment patterns among elderly follicular lymphoma patients diagnosed between 2000 and 2011: An analysis of linked SEER-Medicare data.
o Poster #7563, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia (Hall A)
o Monday, June 5, 2017, 8:00 AM - 11:30 AM
About Xofigo® (radium Ra 223 dichloride) Injection
Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.2
The data being presented at ASCO span prostate, colorectal, liver and thyroid cancers, as well as lymphomas, and includes a subgroup analysis from the Phase II CHRONOS-1 trial of copanlisib in patients with relapsed or refractory follicular lymphoma (FL), the most common subtype of indolent non-Hodgkin's lymphoma (iNHL).1 Additional copanlisib data includes a Phase II study in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive, fast-growing form of NHL. Earlier today, the U.S. Food and Drug Administration (FDA) granted Priority Review designation for Bayer's New Drug Application (NDA) for copanlisib for the treatment of relapsed or refractory FL patients who have received at least two prior therapies, based on the CHRONOS-1 data.
Other data of note includes interim results from the observational REASSURE trial examining real-world patient characteristics and treatment patterns with Xofigo®(radium Ra 223 dichloride) injection and a biomarker analysis from the Phase III RESORCE trial of Stivarga® (regorafenib) tablets. Stivarga recently received approval from the FDA for the treatment of HCC in patients previously treated with sorafenib, making it the first new treatment for HCC in a decade. Notable Bayer studies at ASCO 2017 include the following:
Radium-223 Dichloride (radium-223)
• Patient (pt) Characteristics and Treatment Patterns in the Radium (Ra)-223 REASSURE Observational Study
o Abstract #5042, Poster session: Genitourinary (Prostate) cancer (Hall A)
o Monday, June 5, 2017, 1:15 PM - 4:45 PM
Regorafenib
• Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study
o Abstract #3567, Poster session: Gastrointestinal (Colorectal) Cancer (Hall A)
o Saturday, June 3, 2017, 8:00 AM - 11:30 AM
• Hand–foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC)
o Abstract #3551, Poster session: Gastrointestinal (Colorectal) Cancer (Hall A)
o Saturday, June 3, 2017, 8:00 AM - 11:30 AM
• Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase 3 RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis
o Abstract #4078, Poster session: Gastrointestinal (nonCRC) (Hall A)
o Saturday, June 3, 2017, 8:00 AM - 11:30 AM
Sorafenib
• Interim baseline characteristics from RIFTOS MKI, a global non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)
o Abstract #6084, Poster session: Head and Neck Cancer (Hall A)
o Monday, June 5, 2017 1:15 PM - 4:45 PM
Darolutamide
• ARASENS phase 3 trial of ODM-201 in men with metastatic hormone-sensitive prostate cancer (mHSPC)
o Abstract #TPS5092, Poster session: Genitourinary (Prostate) Cancer (Hall A)
o Monday, June 5, 2017 1:15 PM - 4:45 PM
Copanlisib
• Copanlisib in patients with relapsed or refractory follicular lymphoma
o Poster #7535, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia (Hall A) o Monday, June 5, 2017, 8:00 AM - 11:30 AM
• Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
o Poster #7536, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia (Hall A)
o Monday, June 5, 2017, 8:00 AM - 11:30 AM Other
• Treatment patterns among elderly follicular lymphoma patients diagnosed between 2000 and 2011: An analysis of linked SEER-Medicare data.
o Poster #7563, Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia (Hall A)
o Monday, June 5, 2017, 8:00 AM - 11:30 AM
About Xofigo® (radium Ra 223 dichloride) Injection
Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.2